Alan Menter, MD
Chief, Division of Dermatology
Baylor University Medical Center
Clinical Professor of Dermatology
University of Texas
Southwestern Medical School
Eric M. Ruderman, MD
Professor of Medicine
Associate Chief, Clinical Affairs
Division of Rheumatology
Feinberg School of Medicine
0.5 AMA PRA Category 1 Credit™
What percentage of patients with psoriasis will eventually develop PsA?
What therapies are FDA approved for both skin and joint symptoms?
Psoriatic disease can have a substantial negative impact on patients’ quality of life. The treatments for psoriasis and PsA can overlap, although additional measures should be taken in patients with PsA to slow progression of joint damage, manage pain, and promote mobility for optimal quality of life. This activity will provide learners with strategies for effective multidisciplinary management of psoriasis and PsA.
Dermatologists, dermatology NPs and PAs, rheumatologists, rheumatology NPs and PAs, and other clinicians who co-manage patients with psoriasis and PsA, including general practice/internal medicine clinicians.
Upon completion of this educational activity, the participant should be able to:
- Describe the management of psoriasis, including setting treatment goals and selecting appropriate treatment based on disease and patient characteristics, safety and efficacy, and patient preference.
- Screen patients with psoriasis for PsA and the diagnostic criteria for PsA.
- Discuss strategies to overcome barriers to communication and collaboration with other healthcare professionals to develop a multidisciplinary team for the care of patients with psoriasis and PsA.
Dr. Menter has no conflicts of interest to disclose.
Dr. Ruderman discloses the following conflicts of interest.
Grants/Research Support: Corona
Consultant: AbbVie, Amgen, Celgene, Lilly, Novartis, Janssen Biotech, Pfizer
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose.
Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education, has no conflicts of interest to disclose.
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support Statements
This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
There is no charge for CME credit.
©2018 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Purdue University, Novartis Pharmaceuticals Corporation, or Janssen Biotech, Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.